Summary:
- The article discusses recent clinical research explaining the physiological mechanisms behind weight regain following the cessation of GLP-1 receptor agonists like semaglutide.
- It highlights that the medication alters the brain's homeostatic "set point" for body weight, and when treatment stops, the metabolic and neurological signals driving hunger and fat storage return to their pre-treatment state.
- The findings emphasize that obesity is a chronic, relapsing condition rather than a failure of willpower, and that long-term maintenance requires addressing the underlying biological drivers of weight regulation.